Dr Gruenbaum on the Significance of the FDA Approval of Brexu-cel for MCL

Lore Gruenbaum, PhD, discusses the FDA approval of brexu-cel for mantle cell lymphoma and its significance for the treatment paradigm.

Lore Gruenbaum, PhD, discusses developments in mantle cell lymphoma management that she has her eye on and critical unmet needs in the field.

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.